Oura has received an equity investment from Eli Lilly and Company to accelerate the development of health tools that connect biometric information, dai...
ADmit Therapeutics Competitors or Alternatives
ADmit Therapeutics's top competitors include Alzheon, Alector and AZTherapies.
ADmit Therapeutics VS Alzheon
Alzheon is one of ADmit Therapeutics's top competitors. Alzheon was founded in 2013 in Framingham, Massachusetts. Like ADmit Therapeutics, Alzheon also operates in the Pharmaceuticals & Biotechnology industry. Alzheon generates $3.5M more revenue than ADmit Therapeutics.
ADmit Therapeutics VS Alector
Alector is a top competitor of ADmit Therapeutics. Alector was founded in 2013, and is headquartered in South San Francisco, California. Like ADmit Therapeutics, Alector also competes in the Pharmaceuticals & Biotechnology field. Alector generates $13.4M more revenue vs. ADmit Therapeutics.
ADmit Therapeutics VS AZTherapies
AZTherapies is seen as one of ADmit Therapeutics's top competitors. AZTherapies is headquartered in Boston, Massachusetts, and was founded in 2011. Like ADmit Therapeutics, AZTherapies also operates in the Pharmaceuticals field. AZTherapies generates 180% the revenue of ADmit Therapeutics.
Looking for similar companies to ADmit Therapeutics?
Similar Companies
Pharmaceuticals companies in Catalonia
See 77 companies
Pharmaceuticals & Biotechnology companies in CataloniaSee 150 companies
Pharmaceuticals companies in BarcelonaSee 104 companies
Pharmaceuticals & Biotechnology companies in BarcelonaSee 221 companies
Companies in Catalonia with revenue in $5.0-25M rangeSee 287 companies
Pharmaceuticals companies in SpainSee 506 companies
Pharmaceuticals & Biotechnology companies in SpainSee 1,171 companies
Companies in Catalonia with employees in 1-25 rangeSee 1,774 companies
Companies in Barcelona with employees in 1-25 rangeSee 1,796 companies
Trending News for ADmit Therapeutics and ADmit Therapeutics's Competitors
23andMe data breach settlement: a bipartisan 42-state coalition secured $18 million over the 2023 breach that permanently exposed 6.9 million customers...
Personalis stock reversed lower Friday on a rumor Merck and at least two other suitors are trying to buy the small genomics company. The post Merck Rep...
The Biotech Growth Trust PLC - Eli Lilly to acquire BIOG portfolio company, AtaiBeckley Inc. PR Newswire LONDON, United Kingdom, July 17 17 July 2026 T...
Big pharma is making a big bet that a DMT nasal spray could succeed where daily Prozac pills fall short....
Merck shares climb after the FDA approved Lipfendra, the first oral PCSK9 inhibitor for lowering LDL cholesterol, with the launch expected in weeks....
Eli Lilly has agreed to acquire AtaiBeckley for up to $3.8 billion (€3.3 billion), turning a psychedelic drug developer built from German and British r...
Frequently Asked Questions about ADmit Therapeutics
Who are ADmit Therapeutics's top competitors?
ADmit Therapeutics's top 3 competitors are Alzheon, Alector, AZTherapies.Who is similar to ADmit Therapeutics?
Alzheon is the most similar to ADmit Therapeutics. Alector and AZTherapies are also similar to ADmit Therapeutics.
Are ADmit Therapeutics and Alzheon competitors?
Yes, Alzheon is one of ADmit Therapeutics’s top competitors.